Oramed backs exoskeleton maker Lifeward (NASDAQ: LFWD) in milestone-based funding deal
Oramed Pharmaceuticals (ORMP) has entered a milestone-based funding deal with Lifeward (LFWD), a maker of exoskeleton devices. Lifeward highlighted its strategic partnership with Oramed in an investor presentation, noting potential benefits and funding availability. The company aims to leverage robotics, AI, and reimbursement to grow in the rehabilitation market, with projections of significant market expansion by 2030.
How this was made
The 30-second read
Why it matters
The deal provides non‑dilutive capital tied to product milestones, potentially accelerating commercialization of its exoskeleton platforms and enhancing cash flow prospects.
Market read
The partnership underscores the strategic importance of funding mechanisms in med‑tech growth and may influence valuation of similar rehabilitation‑device companies.
What to watch
Regulatory approvals and reimbursement timelines remain uncertain, which could limit near‑term upside.
Background
Lifeward (NASDAQ:LFWD) is a developer of neuro‑rehabilitation exoskeletons. The company filed an 8‑K announcing a strategic partnership with Oramed Pharmaceuticals that includes milestone‑based funding.
Ticker impact
Lifeward announced a milestone‑based funding partnership with Oramed Pharmaceuticals, providing new capital for its exoskeleton platform.
Modest upside as investors price in additional cash and strategic support.
Funding is non‑dilutive and tied to milestones; however, no financial amount disclosed, limiting immediate price impact.
Market effects
Highlights growing interest in rehabilitation robotics and AI‑driven medical devices.
May boost investor sentiment toward US med‑tech firms focusing on exoskeletons.
Shows cross‑border collaboration between US biotech (Oramed) and med‑tech, relevant for global health‑tech investors.
Counterpoint
Funding milestones may be delayed; without disclosed amounts the partnership could be over‑hyped.
Key entities
- CompanyLifeward Ltd.
NASDAQ‑listed exoskeleton and rehabilitation technology firm.
- CompanyOramed Pharmaceuticals Inc.
Partner providing milestone‑based funding and oral insulin platform.
